Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024
16. Dezember 2024 06:00 ET
|
Serina Therapeutics, Inc.
Meet with Serina’s CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that primarily affects movementContinuous dopaminergic stimulation (CDS) has been shown to reduce the...
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
11. Dezember 2024 06:05 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
12. November 2024 17:00 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced...
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
11. November 2024 17:40 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for...
Serina Therapeutics to Present at the 14th Annual Injectables Summit
02. Oktober 2024 08:30 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04. September 2024 18:42 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
29. Juli 2024 08:30 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery...
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
18. Juli 2024 17:00 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14. Mai 2024 16:05 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
26. März 2024 17:04 ET
|
Serina Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the...